Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M

Syndax Pharmaceuticals Inc

Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.
Net loss $94.2M ($1.10/share) for Q4 2024 vs $72.5M ($1.00) in Q4 2023; full year net loss $318.8M ($3.72).
Cash, equivalents and investments $692.4M; expects current resources to fund to profitability.
Launched Niktimvo in Jan 2025 with Incyte; $350M royalty funding from Royalty Pharma on Niktimvo sales.
sNDA for revumenib in R/R mNPM1 AML expected Q2 2025 based on positive AUGMENT-101 data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.